HarbourVest Partners has led a $1.1bn continuation vehicle for Azurity Pharmaceuticals, supporting QHP Capital’s strategy to extend ownership of the life sciences platform.

Pantheon and Audax Strategic Capital joined the transaction as key investors, highlighting strong institutional demand for high-quality continuation opportunities.

The vehicle provides liquidity to existing limited partners while enabling QHP to retain control and continue executing on Azurity’s long-term growth strategy.

The new capital will support Azurity’s organic growth, business development initiatives, and potential M&A activity, reinforcing its position as a differentiated pharmaceutical platform.

“We are pleased to serve as the lead investor in the transaction which aligns with our strategy of partnering with what we believe are best-in-class general partners and their high performing portfolio companies,” said Nick Bellisario, Managing Director at HarbourVest Partners.

The deal reflects continued momentum in the secondaries market, where continuation vehicles are increasingly used to balance liquidity needs with long-term value creation.

If you think we missed any important news, please do not hesitate to contact us at [email protected].

Can`t stop reading? Read more.